Clinical Trials
51 trialsNCT06840886 2026-05-14
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT04092270 2026-05-13
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06023862 2026-05-06
DOVE
Yonsei University
Phase 2 Recruiting
NCT02446600 2026-05-04
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02839707 2026-05-04
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02502266 2026-04-29
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT04847063 2026-04-14
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05467670 2026-03-04
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT06855069 2025-12-17
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3 Recruiting
NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT04908787 2025-09-11
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04213794 2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1 Terminated
NCT06751485 2024-12-31
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Not yet recruiting
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT06394492 2024-08-09
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT03604653 2022-08-03
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center, Inc.
Completed
NCT01809379 2022-07-08
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Ruhr University of Bochum
Phase 2 Completed
NCT02475772 2022-07-08
A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis
Ruhr University of Bochum
Phase 1 Completed
NCT03542669 2022-03-02
Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer
Peking University People's Hospital
Phase 1 Unknown
NCT03634150 2021-10-26
Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
Immune System Key Ltd
Phase 1/2 Withdrawn
NCT00262990 2020-12-17
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
Phase 3 Completed
NCT01459380 2019-07-22
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003214 2019-05-15
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT01489371 2019-03-12
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT03804866 2019-01-15
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
AGC Biologics S.p.A.
Phase 2 Completed
NCT00662233 2018-10-09
Combination Chemotherapy in Treating Patients With Sarcoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00484432 2018-09-27
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358071 2018-09-27
NGR018
AGC Biologics S.p.A.
Phase 2 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00562185 2017-11-20
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01659554 2017-03-10
HIPEC
Columbia University
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01637532 2016-01-26
PITCH
Leiden University Medical Center
Phase 1/2 Completed
NCT01815294 2015-12-04
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT00945139 2015-07-31
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT01715168 2015-01-15
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Azaya Therapeutics, Inc.
Phase 1 Unknown
NCT00002641 2014-08-08
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00410462 2014-08-08
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT00002477 2013-12-18
Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00025441 2013-12-04
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002489 2013-06-26
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002764 2012-07-11
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00002526 2012-05-15
Chemotherapy in Treating Patients With Advanced Sarcoma
Swiss Cancer Institute
Phase 2 Completed